文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期，新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

Age defining immune effector cell associated neurotoxicity syndromes in aggressive large B cell lymphoma patients treated with axicabtagene ciloleucel.

作者信息

Wudhikarn Kitsada, Bansal Radhika, Khurana Arushi, Hathcock Matthew A, Braksick Sherri A, Bennani N Nora, Paludo Jonas, Villasboas Jose C, Wang Yucai, Johnston Patrick B, Ansell Stephen M, Lin Yi

机构信息

Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, Minnesota, USA.

Division of Hematology and Research Unit in Translational Hematology, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand.

出版信息

Am J Hematol. 2021 Nov 1;96(11):E427-E430. doi: 10.1002/ajh.26330. Epub 2021 Sep 7.

DOI:10.1002/ajh.26330
PMID:34424554
Abstract
摘要

相似文献

[1]
Age defining immune effector cell associated neurotoxicity syndromes in aggressive large B cell lymphoma patients treated with axicabtagene ciloleucel.

Am J Hematol. 2021-11-1

[2]
The impact of obesity and body weight on the outcome of patients with relapsed/refractory large B-cell lymphoma treated with axicabtagene ciloleucel.

Blood Cancer J. 2021-7-1

[3]
CAR-HEMATOTOX: a model for CAR T-cell-related hematologic toxicity in relapsed/refractory large B-cell lymphoma.

Blood. 2021-12-16

[4]
Prophylactic corticosteroid use in patients receiving axicabtagene ciloleucel for large B-cell lymphoma.

Br J Haematol. 2021-8

[5]
Safety of Axicabtagene Ciloleucel for the Treatment of Relapsed or Refractory Large B-Cell Lymphoma.

Clin Lymphoma Myeloma Leuk. 2021-4

[6]
Matching-adjusted indirect treatment comparison of liso-cel versus axi-cel in relapsed or refractory large B cell lymphoma.

J Hematol Oncol. 2021-9-8

[7]
Risk of Second Tumors and T-Cell Lymphoma after CAR T-Cell Therapy.

N Engl J Med. 2024-6-13

[8]
Axicabtagene ciloleucel and brexucabtagene autoleucel in relapsed and refractory diffuse large B-cell and mantle cell lymphomas.

Future Oncol. 2021-4

[9]
Safety profile of chimeric antigen receptor T-cell immunotherapies (CAR-T) in clinical practice.

Eur J Clin Pharmacol. 2021-8

[10]
Novel prognostic scoring systems for severe CRS and ICANS after anti-CD19 CAR T cells in large B-cell lymphoma.

J Hematol Oncol. 2024-8-6

引用本文的文献

[1]
Therapeutic landscape of primary refractory and relapsed diffuse large B-cell lymphoma: Recent advances and emerging therapies.

J Hematol Oncol. 2025-7-1

[2]
The impact of obesity and its related underlying diseases on cytokine release syndrome and the efficacy of CAR-T therapy in treating B-cell malignancies.

Ann Hematol. 2025-3

[3]
Impact of immunological aging on T cell-mediated therapies in older adults with multiple myeloma and lymphoma.

J Immunother Cancer. 2024-12-2

[4]
Chimeric antigen receptor-T cell therapy shows similar efficacy and toxicity in patients with diffuse large B-cell lymphoma aged 70 and older compared to younger patients: A multicenter cohort study.

Hemasphere. 2024-3-20

[5]
CAR t-cell therapy in BOlogNa-NEUrotoxicity TReatment and Assessment in Lymphoma (CARBON-NEUTRAL): proposed protocol and results from an Italian study.

J Neurol. 2023-5

[6]
A systematic framework for predictive biomarkers in immune effector cell-associated neurotoxicity syndrome.

Front Neurol. 2023-2-10

[7]
Clinical Presentation, Risk Factors, and Outcomes of Immune Effector Cell-Associated Neurotoxicity Syndrome Following Chimeric Antigen Receptor T Cell Therapy: A Systematic Review.

Transplant Cell Ther. 2022-6

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索